Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study
View through CrossRef
Abstract
Purpose: Sunitinib has marked pharmacokinetic (PK) & pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore associations with Sunitinib PK/PD (toxicity/response) and progression-free survival (PFS).
Methods: Eligible patients (pts) suitable for Sunitinb therapy. At baseline: (i) PGx: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα). (ii) HNI: pts given IV 800MBq 99mTc-MIBI, imaging data analysed for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2). In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662), and Total SU (metabolite + parent) PK. Associations evaluated between (i) HNI parameters and (2) PGx, with Sunitinib PK, toxicity/response and PFS.
Results: N = 15 pts. The two most significant associations in either direction between PGx variants or HNI parameters (P <0.05) for: (i) PK included: (a) SU logAUC0-14days with HEF, ATP7B-(rs1801246), UGT8-(rs4148254), (b) SU logAUC0-28days, with Td1/2, SLC15A1-(rs8187832), SLC10A2-(rs188096), (c) SU Css, with Td1/2, SLC15A1-(rs8187832) (d) SU Ctrough with TNFα-(rs1799724), ATP7B-(rs1801246), (e) Total SU logAUC0-14days with Td1/2, TNFα-(rs1799724), (f) Total SU logAUC0-28days with Td1/2 and SLCO3A1-(rs2283458), (g) Total SU Css and Td1/2, UGT8-(rs4148254) and (h) Total SU Ctrough with SLC16A1-(rs11585690). (ii) Toxicity (a) Diarrhea Gr1+ with HEF, VEFGR3-(rs307826), AKAP9-(rs7785971) (b) ≥Grade 3 AEs with CBR1-(rs998383) (iii) Overall response rate with SULT1E1-(rs1881668), GSTA2-(rs2180314) (Iv) PFS with CYP4Z1-(rs4926802) and CYP2A6-(rs28399442).
Conclusions: Exploratory associations were observed between Sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics. Further validation is required
Research Square Platform LLC
Title: The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study
Description:
Abstract
Purpose: Sunitinib has marked pharmacokinetic (PK) & pharmacodynamic (PD) interpatient variability.
This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore associations with Sunitinib PK/PD (toxicity/response) and progression-free survival (PFS).
Methods: Eligible patients (pts) suitable for Sunitinb therapy.
At baseline: (i) PGx: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα).
(ii) HNI: pts given IV 800MBq 99mTc-MIBI, imaging data analysed for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2).
In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662), and Total SU (metabolite + parent) PK.
Associations evaluated between (i) HNI parameters and (2) PGx, with Sunitinib PK, toxicity/response and PFS.
Results: N = 15 pts.
The two most significant associations in either direction between PGx variants or HNI parameters (P <0.
05) for: (i) PK included: (a) SU logAUC0-14days with HEF, ATP7B-(rs1801246), UGT8-(rs4148254), (b) SU logAUC0-28days, with Td1/2, SLC15A1-(rs8187832), SLC10A2-(rs188096), (c) SU Css, with Td1/2, SLC15A1-(rs8187832) (d) SU Ctrough with TNFα-(rs1799724), ATP7B-(rs1801246), (e) Total SU logAUC0-14days with Td1/2, TNFα-(rs1799724), (f) Total SU logAUC0-28days with Td1/2 and SLCO3A1-(rs2283458), (g) Total SU Css and Td1/2, UGT8-(rs4148254) and (h) Total SU Ctrough with SLC16A1-(rs11585690).
(ii) Toxicity (a) Diarrhea Gr1+ with HEF, VEFGR3-(rs307826), AKAP9-(rs7785971) (b) ≥Grade 3 AEs with CBR1-(rs998383) (iii) Overall response rate with SULT1E1-(rs1881668), GSTA2-(rs2180314) (Iv) PFS with CYP4Z1-(rs4926802) and CYP2A6-(rs28399442).
Conclusions: Exploratory associations were observed between Sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics.
Further validation is required.
Related Results
The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
Aim
Sunitinib has marked pharmacokinetic (PK) and pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabol...
Denoised VEGFR2 expression relates to sunitinib efficacy in advanced Clear Cell Renal Cell Carcinoma
Denoised VEGFR2 expression relates to sunitinib efficacy in advanced Clear Cell Renal Cell Carcinoma
ABSTRACT
Short summary
Personalized biomarkers can facilitate decision making upon multiple therapeutic options in ccRCC. VEGFR...
Effect of Sunitinib in the Management of Lung Cancer: A Systematic Review of Clinical Trials
Effect of Sunitinib in the Management of Lung Cancer: A Systematic Review of Clinical Trials
Abstract
Introduction
Lung cancer is the most common cancer in terms of both incidence and mortality. Although usually managed with surgery, novel immunotherapies are gradually bec...
Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma
Abstract A54: Potential mechanisms of resistance to targeted agents in human clear cell renal cell carcinoma
Abstract
Targeted therapy with multiple receptor tyrosine kinase inhibitors (RTKI) has led to a substantial improvement in the standard of care for patients with adv...
Abstract 1567: The multi-targeted kinase inhibitor Sunitinib blocks VEGF-C signaling pathway and lymphangiogenesis
Abstract 1567: The multi-targeted kinase inhibitor Sunitinib blocks VEGF-C signaling pathway and lymphangiogenesis
Abstract
Metastasis is the main cause of therapeutic failure and death in cancer patient. Tumor cells disseminate to distant organs through lymphatic and blood vesse...
Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
<b><i>Background:</i></b> This study investigated the efficacy and toxicity of sorafenib and sunitinib as primary treatment for patients with metastatic ren...
Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study
Predictive Factors of Response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs): A Multi-Institutional Study
Imatinib 400 mg is the standard of care for medical treatment of advanced GISTs. In the majority of cases, however, GISTs eventually develop resistance to imatinib. The optimal sec...
Abstract 1145: Therapeutic drug monitoring of Sunitinib in real-world patients
Abstract 1145: Therapeutic drug monitoring of Sunitinib in real-world patients
Abstract
Therapeutic Drug Monitoring (TDM) with model-based adaptive dosing is expected to quickly ensure that exposure levels of anticancer agents are in the adequa...